“A society grows great when older people plant trees whose shade they know they shall never sit in” I truly believe that enhancing the careers of young oncologists is the best way to impact the lives of our patients and shape the future of global oncology #nextgenoncologists

🇮🇹 ✌🏼✌🏼 G Curigliano MD PhD

I express my deepest gratitude to the ESMO - Eur. Oncology community, my esteemed colleagues, and friends for trusting me to serve as the next president of the Society. We are committed to dedicating all our efforts to advancing oncology and improving the lives of our patients.

❓ How to treat CUPs with GI profile • Favorable: FOLFOX/FOLFIRI • Unfavorable: no difference between platinum based-regimens. 📣 Happy to share our contribution on unfavorable GI-like CUPs Thanks to all the co-authors! esmoopen.com/article/S2059-…

Glad to share a new contribution in preventing VTE in cancer patients, which confirmed ONKOTEV score as easy decision making tool for prophylactic anticoagulation. Comparison of Khorana vs. ONKOTEV predictive score to individualize an... sciencedirect.com/science/articl…

📢 Just out on ESMO Open our last contribution on the role of gBRCA-PV in post-PARPi myeloid neoplasms, in pts with ovarian cancer 🚨 In heavily pretreated patients, gBRCA impact seems to be even higher than PARPi exposure Thanks to all the coauthors! sciencedirect.com/science/articl…

Congrats to @GabrAnton 🔥🔥

This just published international cohort study called #INCORPORATE looked at immune checkpoint inhibitors for patients with #metastatic triple-negative #InflammatoryBreastCancer. 🔓Read it here for free until Dec 20⬇️ authors.elsevier.com/c/1k0to3QE--ZB… Carmine Valenza Dario Trapani Paola Zagami, MD

📢 Happy to share our last paper on the role of germline BRCA mut in PARPi-related hematologic AEs ⚠️ No differences between carriers vs. non-carriers Thanks to all the coauthors! Eleonora Nicolò Dario Trapani Luca Boscolo Bielo Lorenzo Guidi G Curigliano MD PhD IEO Università degli Studi di Milano

Excited to share our work at SABCS on metastasis-directed SBRT ☢️ 🏹 for oligoPD #BCSM ! IEO Università degli Studi di Milano 👉Find the concomitant publication at Elsevier kwnsfk27.r.eu-west-1.awstrack.me/L0/https:%2F%2… Carmine Valenza Dario Trapani G Curigliano MD PhD prof. Barbara Jereczek-Fossa Elisabetta Munzone

Special thanks to Assc. Editor G Curigliano MD PhD, Dario Trapani, Lorenzo Guidi, and Liliana Ascione. This article is part of our Special Collection on ADCs in Breast Oncology, led by Paolo Tarantino, and Ilana Schlam. Explore here: journals.sagepub.com/topic/collecti…

📣 Just out our last paper on platinum rechallenge in pts with PROC in @GynOncJnls ⚠️ Platinum-free interval is not adequate to capture platinum resistance 🚨 We need a biomarker driven approach Thanks to all the coauthors! IEO Università degli Studi di Milano gynecologiconcology-online.net/article/S0090-…

Congratulations to Giulia Marvaso and prof. Barbara Jereczek-Fossa 🎉🎉 IEO

📣 Excited to share our latest review on bispecific antibodies in hematologic and solid tumors, now published in the ASCO Educational Book! A deep dive into mechanisms, clinical progress, and future directions. G Curigliano MD PhD Julian Etessami Carmine Valenza ascopubs.org/doi/pdf/10.120…

🖥️🎯 Happy to present at #AACR2025 the benchmark testing of our academical, independent and budget-friendly trial matcher OncoSolver (OS), that may improve the workflow of patient referrals to trials. Time to start its clinical validation at IEO G Curigliano MD PhD

Happy to share our latest work published in Annals of Oncology: 🚫 Lack of ctDNA clearance during neoadj IO may identify patients unlikely to achieve pCR. ⚠️ ctDNA clearance has limited confirmatory power due to low specificity and high heterogeneity. Thanks to all coauthors!

“We shall not cease from exploration And the end of all our exploring Will be to arrive where we started And know the place for the first time”. (T. S. Eliot) MPH in Clinical Effectiveness Harvard T.H. Chan School of Public Health

🎓 Sei pronto a diventare uno dei migliori oncologi del futuro? Scegli Università degli Studi di Milano per la tua #ScuolaDiSpecializzazione in #Oncologia: ✅ Formazione d'eccellenza 🌍 Visione internazionale 🏆 UnIMI: dove nascono i migliori specialisti. #Oncologia ESMO - Eur. Oncology AIOM

Perché scegliere la scuola di oncologia de Università degli Studi di Milano? G Curigliano MD PhD IEO